Romidepsin - Celgene Corporation

Drug Profile

Romidepsin - Celgene Corporation

Alternative Names: Depsipeptide; FK 228; FR 901228; Istodax; NSC 630176; NSC 630176D; RMD

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Canadian Cancer Trials Group; Celgene Corporation; Lymphoma Academic Research Organisation; University of Birmingham; University of California at San Francisco; University of Kansas Medical Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Depsipeptides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Breast cancer; Multiple myeloma; T cell lymphoma; T-cell leukaemia
  • Phase I Diffuse large B cell lymphoma; Haematological malignancies
  • Discontinued Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 19 Sep 2018 Celgene completes a phase I trial in Diffuse large B cell lymphoma and Peripheral T-cell lymphoma (Combination therapy) in Canada (IV) (NCT01846390)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Columbia University and Celgene initiates enrolment in a phase I/II trial for Peripheral T cell lymphoma (Combination therapy, Second line therapy or greater) in USA (NCT03161223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top